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Abstract
More than 20 genetic loci have been associated with risk for Alzheimer’s disease (AD), but 
reported genome-wide significant loci do not account for all the estimated heritability and provide 
little information about underlying biological mechanisms. Genetic studies using intermediate 
quantitative traits such as biomarkers, or endophenotypes, benefit from increased statistical power 
to identify variants that may not pass the stringent multiple test correction in case–control studies. 
Endophenotypes also contain additional information helpful for identifying variants and genes 
associated with other aspects of disease, such as rate of progression or onset, and provide context 
to interpret the results from genome-wide association studies (GWAS). We conducted GWAS of 
amyloid beta (Aβ42), tau, and phosphorylated tau (ptau181) levels in cerebrospinal fluid (CSF) 
from 3146 participants across nine studies to identify novel variants associated with AD. Five 
genome-wide significant loci (two novel) were associated with ptau181, including loci that have 
also been associated with AD risk or brain-related phenotypes. Two novel loci associated with 
Aβ42 near GLIS1 on 1p32.3 (β = −0.059, P = 2.08 × 10−8) and within SERPINB1 on 6p25 (β = 
−0.025, P = 1.72 × 10−8) were also associated with AD risk (GLIS1: OR = 1.105, P = 3.43 × 
10−2), disease progression (GLIS1: β = 0.277, P = 1.92 × 10−2), and age at onset (SER-PINB1: β 
= 0.043, P = 4.62 × 10−3). Bioinformatics indicate that the intronic SERPINB1 variant (rs316341) 
affects expression of SERPINB1 in various tissues, including the hippocampus, suggesting that 
SERPINB1 influences AD through an Aβ-associated mechanism. Analyses of known AD risk loci 
suggest CLU and FERMT2 may influence CSF Aβ42 (P = 0.001 and P = 0.009, respectively) and 
the INPP5D locus may affect ptau181 levels (P = 0.009); larger studies are necessary to verify 
these results. Together the findings from this study can be used to inform future AD studies.
Keywords
Alzheimer’s disease; Endophenotype; Cerebrospinal fluid biomarkers; Genome-wide association 
study
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Introduction
More than five million Americans suffer with Alzheimer’s disease (AD), the most common 
neurodegenerative disease leading to progressive cognitive decline, and this number 
continues to increase as there are currently no effective methods to treat or prevent disease. 
Several genome-wide association studies (GWAS) have identified at least 24 loci containing 
common variants associated with AD risk [37, 39, 48, 56]. AD is a complex disease that is 
highly heritable, with an estimated heritability as high as 79% in twin studies [31] and 
genetic variance analyses estimate >53% of the variance in AD status can be explained by 
common variants (minor allele frequency, MAF > 1%) [64]. Polygenic studies have 
illustrated the genetic complexity underlying AD; recent studies using polygenic risk scores 
(PRS) calculated by combining the small effects of independent SNPs associated with AD 
risk (P < 0.5) provided AD risk prediction accuracy, as measured by area under the receiver 
operating curve (AUC) > 0.74, which is near the maximum AUC (0.82) [22, 23]. These 
studies indicate many genetic loci combine to increase risk for AD, most of the genetic risk 
loci are tagged by common variants (MAF > 1%), and that these loci, individually, have 
small effects on disease. These findings reveal that most AD risk variants have not passed 
the strict significance threshold required for multiple-test correction in GWAS, even in large 
studies such as the landmark study by the International Genomics of Alzheimer’s Project 
(IGAP), involving more than 74,000 total individuals, which identified 11 novel loci 
associated with AD risk [48]. It is also important to note that most AD susceptibility loci 
identified in these GWAS are gene-dense regions and many significantly associated SNPs 
are non-coding (intronic or intergenic), making it difficult to determine which genes are 
involved or how identified variants influence these genes. Studies integrating alternative 
phenotypes, gene expression, and other omics data are important for understanding the 
underlying biology of AD.
There is significant evidence that AD pathology is present several years before the onset of 
clinical symptoms [25, 26, 41, 55]. Consequently, AD case–control GWAS can be 
confounded by the presence of preclinical “controls”. Case– control-based GWAS are also 
limited to identifying genetic associations for disease risk; results from these studies do not 
provide information about other aspects of disease such as age at onset (AAO) or disease 
progression, or information about underlying biological mechanisms involved in 
pathogenesis. Endophenotypes are quantitative traits strongly associated with disease that 
also share genetic architecture with disease; therefore, genetic studies of endophenotypes are 
a powerful approach to identify loci associated with complex traits without many of the 
limitations of case–control studies. Cerebrospinal fluid (CSF) amyloid-beta1–42 (Aβ42) and 
phosphorylated tau (ptau181) are well-established AD endophenotypes [7, 13–15]. CSF 
ptau181 levels are elevated in AD cases and positively correlate with the number of 
neurofibrillary tangles, while CSF Aβ42 levels are lower in cases and correlate negatively 
with plaque load [43, 59, 72]. Increased CSF ptau181 is predictive for cognitive decline and 
progression from mild cognitive impairment to AD [2, 16]. Some genetic variants associated 
with AD also influence CSF levels of ptau181, Aβ42, or both [13, 44]. We previously 
performed GWAS of CSF tau, ptau181, and Aβ42 on 1269 participants (591 cases, 687 
controls) and identified four genome-wide significant loci associated with tau and ptau181, 
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including a novel locus that also associated with AD risk, tangle pathology, and cognitive 
decline [13]. This study has been expanded more than twofold to 3146 participants across 
nine cohorts with CSF and genome-wide genotype data (Table 1), providing additional 
power to identify more novel loci associated with ptau181, Aβ42, and AD.
Methods
Ethics statement
The Institutional Review Boards of all participating institutions approved the study and 
research was carried out in accordance with the approved protocols. Written informed 
consent was obtained from participants or their family members.
Cohort descriptions
CSF tau, ptau, and Aβ42 were measured in 3146 individuals from nine different studies. 
There were 805 individuals (29.34% cases) enrolled in studies at the Charles F. and Joanne 
Knight Alzheimer’s Disease Research Center (Knight ADRC), 787 individuals (more than 
71% cases) from Alzheimer’s Disease Neuroimaging Initiative (ADNI; 390 from ADNI1 
and 397 from ADNI2), 184 individuals (5.43% cases) from BIOCARD: Predictors of 
Cognitive Decline Among Normal Individuals (BIOCARD), 105 individuals (no AD status) 
from Saarland University in Homburg/Saar, Germany (HB), 433 individuals (22.17% cases) 
from Mayo Clinic (MAYO), 293 individuals (all cases) from Skåne University Hospital, 
Sweden (SWEDEN), 164 (62.8% cases) from studies at Perelman School of Medicine at the 
University of Pennsylvania (UPENN), and 375 (33.33% cases) from studies at the 
University of Washington (UW). Table 1 shows the demographic data for each study. 
Clinical assessments, CSF collection, and proteins were measured by each site. Clinical 
dementia rating (CDR) was available for 86% of the total data set. The CDR is a five-point 
scale used to describe the overall dementia severity for each individual (no dementia = 0, 
very mild = 0.5, mild = 1, moderate = 2, and severe = 3). Individuals with CDR = 0 were 
categorized as controls, cases were defined as individuals with CDR > 0.
Genotyping and imputation
Samples were genotyped with the Illumina 610 or Omniexpress chip. Stringent quality 
control (QC) criteria were applied to each genotyping array separately before combining 
genotype data. The minimum call rate for single nucleotide polymorphisms (SNPs) and 
individuals was 98% and autosomal SNPs not in Hardy–Weinberg equilibrium (P < 1 × 
10−6) were excluded. X-chromosome SNPs were analyzed to verify sex identification. 
Unanticipated duplicates and cryptic relatedness (Pihat ≥ 0.25) among samples were tested 
by pairwise genome-wide estimates of proportion identity-by-descent, and when a pair of 
identical or related samples was identified, the sample from Knight ADRC or with a higher 
number of variants that passed QC was prioritized. EIGENSTRAT [61] was used to 
calculate principal components. APOE ε2, ε3, and ε4 isoforms were determined by 
genotyping rs7412 and rs429358 using Taqman genotyping technology as previously 
described [14, 15, 44]. The 1000 Genomes Project Phase 3 data (October 2014), SHAPEIT 
v2.790 [18], and IMPUTE2 v2.3.2 [40] were used for phasing and imputation. Individual 
genotypes imputed with probability <0.90 were set to missing and imputed genotypes with 
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probability ≥0.90 were analyzed as fully observed. Genotyped and imputed variants with 
MAF < 0.02 or IMPUTE2 information score <0.30 were excluded, leaving 7,358,575 
variants for analyses.
Data normalization for statistical analyses
Prior to combining data for analyses, CSF levels of tau, ptau, and Aβ42 were log10-
transformed to approximate a normal distribution and the mean from each data set was 
standardized to zero to account for the different platforms used by different studies to 
measure protein levels. There were no significant differences in the transformed and 
standardized values for the different studies. Study, age, sex, and the first two principal 
components were identified as confounding factors by stepwise regression analyses for each 
protein and corrected for in applicable analyses.
Experimental design and data modeling
Studies by our group, and others, have demonstrated that when there is GWAS data available 
for all samples, a one-stage GWAS of combined data from both stages of a two-stage GWAS 
provides more power to identify genetic association than analyzing the groups separately, 
despite the fact that the one-stage GWAS requires a more stringent threshold to determine 
significance [13–15, 19, 70]. To maximize the power in our analyses, we performed a one-
stage joint-GWAS. The CSF levels were measured with different platforms and at different 
sites, consequently the raw values could not be combined. Instead, the raw values were 
log10-transformed to approximate a normal distribution within each separate study and 
centralized by each study mean. We have used this approach in previous studies and 
demonstrated that it is an effective way to correct for study differences [13, 19]. We also 
performed analyses to ensure the results were not confounded by any study bias; to 
determine if the top hits were being driven by any individual study, we analyzed each dataset 
separately and performed meta analyses. The directions of effect for the genome-wide 
significant signals for Aβ42 and ptau181 were consistent across studies when analyzed 
separately and results from meta-analyses of the individual studies were consistent with the 
joint results even after removing cohort from previous study (Supplementary Figs. 1–3).
Alternative mixed model method to normalize Aβ42
Since CSF levels of Aβ42 are lower in AD cases than controls, begin decreasing prior to 
clinical symptom onset [25, 26, 43, 59, 72], and the studies in this dataset varied in 
proportion of cases to controls, we wondered if a mixture modeling approach would be more 
appropriate for standardizing the data between studies instead of centering on the mean of 
each study. This method was successfully used previously to classify AD cases in two 
independent cohorts with at least 94% sensitivity [17]. Mixture modeling is a statistical 
method for estimating subpopulations within an overall group; in this case we assumed two 
normally distributed subgroups within each dataset representing individuals with low Aβ42, 
therefore likely to be AD cases or preclinical, and with high Aβ42, likely to be cognitively 
normal controls. Using an expectation–maximization algorithm, we calculated estimated 
means, standard deviations, and subgroup proportions for each study. Based on the 
assumption of two univariate normal distributions within each study we obtained two 
estimated means (µ1 and µ2), two estimated standard deviations (σ1 and σ2), and two 
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estimated mixing proportions (λ1 and λ2). We used these results to calculate the intersection 
of the estimated Gaussian curves using the following formula (Eq. 1):
(1)
analyte, including study, age, sex, and the first two principal components as covariates in the 
default model [11]. The genomic inflation factor was λ = 1.02 for ptau181 and λ = 1.03 for 
tau and Aβ42 (Supplementary Fig. 7). There were no novel genetic associations identified 
for CSF tau levels (Supplementary Fig. 8 and Supplementary Table 2) but we did identify 
novel associations for ptau181 and Aβ42 (Figs. 1, 2; Table 2; Supplementary Tables 3, 4). 
Conditional analyses were conducted to identify additional independent signals in a locus by 
adding the SNP with the smallest P value as a covariate into the default regression model 
and testing all remaining regional SNPs for association (Supplementary Figs. 9, 10). AD 
status, CDR, APOE alleles, APOE ε4 carrier status, Aβ42, or ptau181 levels were corrected 
for in additional analyses to determine the effects of these phenotypes on the genetic 
associations (Supplementary Fig. 11 and Supplementary Table 5–Supplementary Table 8). 
The combined dataset was stratified by AD status and cases and then centered the log10-
transformed Aβ42 levels to the intersection of the curves instead of the means for each study 
(Supplementary Table 1). CSF Aβ42 thresholds have been determined previously for both 
ADNI (192 pg/mL) [69] and ADRC (500 pg/mL) [25]; the calculated intersects were 
comparable to these values (182 and 548 pg/mL, respectively, Supplementary Table 1). The 
density plots of the estimated subpopulations for each study ft the overall distributions 
reasonably well, but after accounting for AD status the model did not appear significantly 
different than standardizing to the overall mean (Supplementary Figs. 4, 5). There was no 
difference between the two methods in a single variant analysis of the mixed model 
standardized CSF Aβ42 levels and the levels centered at the study mean (Supplementary Fig. 
6).
The intersect was log10-transformed and subtracted from the log10-transformed values of 
Aβ42 (Supplementary Figs. 4, 5 and Supplementary Table 1). When the singlevariant 
analysis was repeated using these normalized values for Aβ42, the results were comparable 
to those from the mean normalized values (Supplementary Fig. 6). Therefore, to be 
consistent, we used the mean normalized values in all analyses.
Association testing
The additive linear regression model in PLINK v1.9 [11] was used for single-variant 
analyses for each controls were analyzed separately for single-variant associations 
(Supplementary Table 8). Statistical significance for the single-variant analyses was based 
on the commonly used threshold from Bonferroni correction of the likely number of 
independent tests in genome-wide analyses (P < 5 × 10−8). Manhattan plots and regional 
association plots were created using the R package qqman v0.1.2 [74] and LocusZoom v1.3 
[62], respectively.
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Meta-analyses
To test for potential systematic differences between the datasets, each study was analyzed 
separately for the most significant SNPs from the joint analyses. Covariates were age, sex, 
and the first two principal components. Meta-analyses of the results from the separate 
datasets were performed using METAL (version released 2011-03–25) [80]. The METAL 
default analysis scheme was used with sample size and beta for each SNP taken into account 
when combining P values across studies. For the genome-wide significant signals, the nine 
studies showed consistent direction of effect individually, and meta-analysis results were 
consistent with the joint results (Supplementary Figs. 1, 2). After removing the samples that 
comprised the previously published study [13], the meta-analysis results remained consistent 
with the joint results (Supplementary Fig. 3). Forest plots were generated using the R 
package rmeta v2.16.
Association with AD risk, progression, AAO
Results from independent analyses of different cohorts for AD risk [48], AAO (personal 
communication: Huang & Goate), and disease progression were analyzed to determine 
whether loci associated with CSF tau, ptau181, and Aβ42 were also associated with other AD 
phenotypes. Results for the most significantly associated SNPs for CSF tau, ptau181, and 
Aβ42 are reported here from the largest previously published two-stage meta-analysis of 
GWAS for AD risk consisting of a total 25,580 cases and 48,466 controls [48], and a 
recently published genome-wide survival analysis of AAO consisting of 39,855 individuals 
(personal communication: Huang & Goate). To determine disease progression in an 
independent cohort of 1530 individuals, we utilized the CDR Sum of Boxes (CDR-SB) 
which has been demonstrated to accurately stage dementia severity [57, 58]. Overall CDR is 
derived from scores in six individual categories (boxes) of memory, orientation, problem 
solving, community involvement, involvement in home and hobbies, and personal care; 
CDR-SB is a sum of the six boxes which provides a semi-continuous measure of 
symptomatic AD dementia from 0 (cognitively normal) to 18 (the most severe dementia). 
Disease progression from longitudinal studies at ADNI (n = 728) and Knight ADRC (n = 
802) was modeled as the change in CDR-SB per year, adjusting for age, sex, baseline CDR, 
follow-up time, level of education, site, and PCs (Supplementary Table 9). Samples with ≥3 
clinical assessments over 1.5 years after being diagnosed with AD were selected for the 
analysis and a mixed-model repeated measure framework was used to account for 
correlation between repeated measures in the same individual. We selected the appropriate 
optimal variance–covariance structure that minimizes the Akaike Information Criterion for 
testing the null model AR1 [14].
Functional annotation
All SNPs below the suggestive significance threshold (P = 1 × 10−5) were taken forward for 
functional annotation using ANNOVAR version 2015-06–17 [77] and examined for potential 
regulatory functions using RegulomeDB v1.1 [8] and HaploReg v4.1 [78]. The search tools 
on the Genotype-Tissue Expression (GTEx) Analysis Release V6, dbGaP Accession 
phs000424.v6.p1 portal [33], data from the Brain eQTL Almanac (Braineac) [73] analyzed 
with the R package MatrixEQTL [68], and the Blood eQTL browser [79] were utilized to 
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determine if genome-wide significant SNPs were reported eQTLs. The Brain RNA-Seq 
database (http://web.stanford.edu/group/barres_lab/brainseqMariko/brainseq2.html) was 
mined to determine if genes of interest were expressed in the brain and in which cell types 
[84].
Summary data-based mendelian randomization
To prioritize the putative causal variant from the ptau181 and Aβ42 associated variants, we 
used the Summary data-based Mendelian Randomization (SMR) method which tests the 
functional association between gene expression levels (measured by probes) and a trait (such 
as CSF protein levels) through the regression of estimated effect sizes [85]. Based on the 
assumptions of Mendelian randomization, any gene–trait association identified in this 
analysis should be free of confounding from non-genetic factors. To distinguish causality of 
a single variant on both gene expression and the trait vs linkage of two distinct genetic 
variants in LD with one affecting expression and one affecting the trait, the SMR method 
uses a heterogeneity (HEIDI) test. For the SMR analysis, we utilized the estimates of SNP 
effects on gene expression from summary data of a large-scale eQTL study with gene 
expression measured in peripheral blood (Blood eQTL browser) [79] and gene expression 
data from Cardiogenics measured in macrophages [35]. There were 3000 SNPs present in 
both the blood eQTL data and the GWAS results so the statistical significance threshold was 
defined (based on Bonferroni correction) as P < 1.67 × 10−5 for the associations between 
eQTL in blood and CSF GWAS loci. Focusing on the SERPINB1 gene region (from the 6p 
terminal to 10 Mb after the defined SERPINB1 transcription region) in the macrophage 
eQTL data, there were 4336 SNPs; therefore, the statistical significance threshold was 
defined as P < 1.15 × 10−5. The HEIDI threshold was set at P > 0.05 to be conservative; 
since the null hypothesis is that there is only one causal variant, a P > 0.05 indicates the 
variant that passed the SMR test is the causal variant.
Genetic variance estimation
The Genome-wide Complex Trait Analysis (GCTA) v1.25.2 tool [82] was used to estimate 
the proportion of phenotypic variance explained by the common (MAF > 0.02) imputed and 
genotyped autosomal variants. The restricted maximum likelihood (REML) analysis was 
performed on the log10-transformed standardized analyte values adjusted for age and gender 
with the first two principal components as covariates. Results are reported in Supplementary 
Table 10.
Since it was reported that estimated h2 may be biased if causal variants are enriched in areas 
with lower or higher LD than average [81], we also used GCTA to calculate segment-based 
LD scores (segment length = 200 kb) for all SNPs in the REML analysis and plotted the 
number of SNPs from the single-variant analyses of Aβ42 and ptau181 with P < 1 × 10−5 
(Supplementary Fig. 12). Since the most significantly associated SNPs showed LD 
heterogeneity, and the method can be applied to imputed GWAS data, we used the LD- and 
MAF-stratified genomic-REML (GREML-LDMS) method [81] in GCTA to estimate h2 for 
each LD quartile and calculate a total h2 estimate (Supplementary Table 10). The GCTA-
GREML power calculator (http://cnsgenomics.com/shiny/gctaPower) [76] was used to 
calculate the power of the REML and GREML-LDMS analyses with the actual sample sizes, 
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estimated h2, α = 0.05, and genetic variance = 2 × 10−5 as parameters (Supplementary Table 
10).
Polygenic risk score
PRS were calculated using a weighted sum of the AD risk alleles reported by IGAP [48]. 
Weights for SNPs outside the APOE region were calculated by transforming the reported 
odds ratios by a base-2 logarithm. Proxy SNPs were utilized if the reported SNPs were 
unavailable in our data or did not pass QC; proxies were selected with the highest R2 and D’ 
values to the reported IGAP SNP in our genetic data and in 1000 Genomes. Since APOE has 
a large effect on AD risk and CSF protein levels, we calculated a default PRS without 
APOE. The effects of APOE genotype on AD risk are not additive, so APOE genotypes 
were weighted by the effects reported previously for each genotype (ε2/ε2 OR = 0.6, ε2/ε3 
OR = 0.6, ε2/ε4 OR = 2.6, ε3/ε4 OR = 3.2, ε4/ε4 OR = 14.9) [29]. The SNPs that 
composed the PRS are listed in Supplementary Table 11. The PRS were calculated (with and 
without APOE genotype) using the score function in PLINK v1.90b3.42 [11], including the 
no-mean-imputation option to ensure scores would not be imputed for missing genetic data. 
The resulting mean score per allele was multiplied by the allele count to generate a total 
PRS.
Results
Reproduction of previously reported associations with CSF Aβ42, tau, and ptau181
As reported previously, the most significant variant associated with CSF levels of Aβ42, tau, 
and ptau181 was a proxy SNP for APOE ε 4 (r2 = 0.726, D’ = 1), rs769449[A] (Aβ42 β = 
−0.117, P = 9.02 × 10−47; tau β = 0.082, P = 1.95 × 10−16; ptau181 β = 0.091, P = 2.56 × 
10−18) [13]. In the current analyses, the effects were similar to what was previously reported 
with more significant P values due to the larger sample size (Aβ42 β = −0.101, P = 4.78 × 
10−94; tau β = 0.078, P = 4.05 × 10−29; ptau181 β = 0.081, P = 9.51 × 10−35). While there 
were no other loci associated with Aβ42 in the previous GWAS, two loci outside the APOE 
locus were identified to be associated with CSF tau and ptau181 [13]. We also replicated the 
previously reported loci for ptau 181 on 3q28 (rs9877502[A] near GMNC, β = 0.044, P = 
1.68 × 10−7) and on 9p24.2 (rs514716[C] on GLIS3, β = −0.072, P = 3.22 × 10−9) were both 
genome-wide significant in this larger study (rs9877502[A], β = 0.032, P = 6.35 × 10−9; 
rs514716[C], β = −0.049, P = 2.94 × 10−8) (Table 2, Supplementary Fig. 13; see 
Supplementary Table 4 for all loci with P < 1 × 10−5) [13].
A small GWAS of AD CSF biomarkers from 374 ADNI participants (102 controls) 
identified variants in EPC2 associated with CSF levels of tau and the Tau/Aβ42 ratio [46]. In 
our current analyses, there were no genome-wide significant, or suggestive, associations 
with the EPC2 locus (tau: β = 0.005, P = 0.428; Tau/Aβ42 ratio β = 0.072, P = 0.017), but 
interestingly the strongest association was for Aβ42 (β = −0.016, P = 3.77 × 10−4; 
Supplementary Fig. 14). Another early GWAS of CSF levels from 410 ADNI participants 
(119 controls) did not identify any genome-wide significant variants for CSF Aβ42, ptau181, 
or tau in cases, but found three genome-wide significant signals for Aβ42 in controls 
(CYP19A1, NCAM2, and ARL5B) [36]; none of these loci were associated with Aβ42 in 
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our current analyses of the joint dataset, cases-only, or controls-only (P > 0.1). A recent 
GWAS with only AD cases (N = 363) reported that SNPs located in the SUCLG2 region 
were associated with CSF Aβ42 levels [63] but this region was not associated with Aβ42 in 
any of the current analyses of the joint dataset, cases-only, or controls-only (P > 0.1). 
FRA10AC1 variants were associated with CSF Aβ42 levels in a two-stage GWAS of data 
from ADNI (two discovery sets: N = 391 and N = 385; replication set N = 204), and 
although there were no genome-wide significant signals within the FRA10AC1 locus in the 
current analyses, there was a near suggestive association between Aβ42 and indel 
rs143151810[-] (β = −0.033, P = 8.13 × 10−5; Supplementary Fig. 14), which is in high LD 
with the SNP identified in the other study, rs10509663[G] (r2 = 0.987, D’ = 0.997), and both 
associations showed the same direction of effect on Aβ42 levels [51].
APOE locus significantly influences CSF levels of ptau181 and tau independently of Aβ42
As we reported previously, the APOE region was still significantly associated with ptau181 
after including CSF Aβ42 levels in the analysis (rs769449[A]: default, βSNP = 0.079, P = 
5.30 × 10−33; adjusted for Aβ42 levels, βSNP = 0.046, P = 2.08 × 10−11), and in the current 
analysis the association between rs769449[A] and ptau181 remained genome-wide 
significant after including the interaction between Aβ42 levels and APOE genotype in the 
model (βSNP = 0.042, P = 1.65 × 10−8), suggesting APOE may influence tau pathology 
independently of Aβ42 and supporting our previous findings (Supplementary Fig. 11 and 
Supplementary Table 5) [13]. Similar results were observed with CSF tau as well (default, 
βSNP = 0.077, P = 6.75 × 10−28; adjusted for Aβ42 levels, βSNP = 0.048, P = 4.11 × 10−11; 
Aβ42 and APOE genotype interaction, βSNP = 0.045, P = 1.04 × 10−8). Low Aβ42 levels 
(ADRC < 500 pg/mL and ADNI < 192 pg/ mL) have been associated with amyloid positron 
emission tomography (PET-PIB) evidence of Aβ deposition [25, 69]. To determine if the 
possible presence of Aβ pathology influenced the effect of the APOE locus on ptau181 levels 
as we reported previously [13], we stratified the data from ADRC, ADNI1, and ADNI2 by 
high and low levels of Aβ42 and found the association between APOE locus and ptau181 
levels in both groups with a higher effect size in the individuals with low Aβ42 (β = 0.055, P 
= 2.12 × 10−7) than those with high Aβ42 (β = 0.037, P = 1.05 × 10−2).
We wanted to determine if the signal in the APOE locus was driven entirely by APOE 
genotype (APOE ε2, ε3, and ε4), or if there was an independent signal influencing CSF 
levels of ptau181 and Aβ42, so we performed conditional analyses on APOE genotype 
accounting for both ε 2 and ε 4 effects. The APOE genotype showed the strongest 
association with CSF levels of ptau181 (β = 0.042, P = 3.13 × 10−40) and Aβ42 (β = −0.053, 
P = 8.88 × 10−114) after correcting for age, sex, study, and two principal components. The 
association between the top hit in the APOE locus (rs769449) and ptau181 or Aβ42, remained 
significant, but not genome-wide significant, after adding APOE genotype to the model 
(ptau181: β = 0.034, P = 1.07 × 10−3; Aβ42: β = −0.036, P = 1.65 × 10−6) suggesting that 
there may be a signal in this region independent of APOE ε2, ε3, and ε 4 (Supplementary 
Table 12). To further explore this finding, we conditioned on the most significant SNP 
(rs769449), which is in high LD for the APOE ε 4 allele (rs429358[C], D’ = 1, r2 = 0.726). 
We found that although the associations between APOE genotype and ptau181 and Aβ42 
decreased, they remained genome-wide significant (conditioned: β = 0.029, P = 5.91 × 10−9 
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and β = −0.040, P = 2.28 × 10−28, respectively) (Supplementary Table 12). Together, these 
results suggest that most of the signal in this region is driven by APOE genotype, but 
additional independent SNPs in this region may influence CSF levels of both ptau181 and 
Aβ42.
Novel associations in single-variant regression analyses for Aβ42 and ptau181
The genomic inflation was minimal in all analyses suggesting no evidence of confounding 
by systematic biases (default model λ = 1.03 for Aβ42 and tau, 1.02 for ptau181; 
Supplementary Fig. 7). In addition to the loci reported previously, two novel genetic 
associations with CSF ptau181 were identified on 13q21.1 (rs9527039[C] near PCDH8, β = 
−0.061, P = 5.95 × 10−9) and 18q23 (rs12961169[T] near CTDP1, β = 0.050, P = 5.12 × 
10−10) (Fig. 1; Table 2). We also identified, for the first time, two genome-wide significant 
loci outside of the APOE region associated with CSF Aβ42 on 1p32.3 (rs185031519[G] near 
GLIS1, β = −0.059, P = 2.08 × 10−8) and on 6p25 (rs316341[G] within SER-PINB1, β = 
−0.025, P = 1.72 × 10−8) (Fig. 2; Table 2; see Supplementary Table 3 for all loci with P < 1 
× 10−5). Conditioning on the most significant SNPs in each of these identified loci did not 
reveal any additional genome-wide significant signals (Supplementary Figs. 9, 10).
When clinical dementia rating (CDR) or clinical status were included in the model for either 
Aβ42 or ptau181, the results for the top loci were not significantly different than the default 
model (Supplementary Table 7), and when the analyses were stratified by AD status, the 
betas were similar for cases and controls (Supplementary Table 8). When individuals were 
stratified by high or low CSF Aβ42 levels (Aβ42 threshold: ADRC = 500 pg/ mL [25], ADNI 
= 192 pg/mL [69]), the betas for the top loci were similar between the two groups 
(Supplementary Table 8). These results suggest that all of the individuals in this study 
contributed to the associations with CSF Aβ42 and ptau181 levels, independent of status or 
amyloid pathology.
Effects of associated genetic loci on other AD phenotypes
Since the purpose of studying these AD endophenotypes was to identify genetic factors 
associated with AD, we tested the genome-wide significant loci for associations with AD 
risk [48], rate of AD progression [58], or AAO (personal communication: Huang & Goate) 
in independent cohorts. The loci associated with Aβ42 were also associated with risk, AAO, 
and/or progression (Table 3). The GLIS1 locus was associated with lower CSF Aβ42 levels 
(rs185031519[G], β = −0.059, P = 2.08 × 10−8), increased AD risk (rs114122417[A], OR = 
1.105, P = 0.034) [48], and faster disease progression (rs185031519[G], β = 0.277, P = 
0.019) (Table 3). The intronic SERPINB1 variant, rs316341[G], was associated with earlier 
AAO (β = 0.043, P = 4.62 × 10−3) as well as lower Aβ42 (β = −0.025, P = 1.72 × 10−8) 
(Table 3). Although the loci associated with ptau181 that we reported previously were 
associated with AD risk and AAO [13], we did not find evidence that the novel loci were 
associated with risk, AAO, or progression (Table 3). We were unable to test other AD 
phenotypes such as brain atrophy or neuropathology. However, both the MAPT locus on 
17q21, which is associated with CSF tau levels in the presence of Aβ deposition [45], and 
the GMNC locus, which was associated with CSF levels of tau (β = 0.040, P = 3.07 × 10−11) 
and ptau181 (β = 0.035, P = 7.62 × 10−10), as well as AD risk (OR = 1.044, P = 9.08 × 10−3), 
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tangle pathology (P = 0.039, reported previously) and cognitive decline (P = 4.86 × 10−5, 
reported previously) [13], have recently been associated with total brain volume in a meta-
analysis of 26,577 individuals of European descent [1], suggesting variants associated with 
ptau181 may also be associated with other brain-related or neurodegenerative phenotypes.
Bioinformatics annotation
None of the genotyped or imputed SNPs in the genome-wide significant loci for Aβ42 or 
ptau181 were coding variants (R2 > 0.5, Supplementary Tables 3, 4). In an effort to pinpoint 
functional genes influencing CSF protein levels, we searched for SNPs in the genome-wide 
significant loci with cis expression quantitative trait locus (eQTL) effects in human tissues. 
The top SNPs associated with Aβ42 on 6p25 have eQTL effects for SERPINB1 in 
transformed fibroblasts (rs316341[G]: β = 0.24, P = 1.3 × 10−7) and whole blood 
(rs316339[A]: Z score = 28.96, P = 2.2 × 10−184), and rs316339 had the strongest eQTL 
effect on SERPINB1 in the hippocampus (β = 0.30, P = 3.90 × 10−5) (Table 4). To determine 
if the putative causal variant is the same for SERPINB1 expression and Aβ42 levels, we 
utilized Summary data-based Mendelian Randomization (SMR) [85] to test the Westra 
whole blood expression data [79]. One SERPINB1 variant, rs316339, which is in LD with 
rs316341 (D ‘ = 1, r2 = 0.993; CSF Aβ42 β = −0.025, P = 1.76 × 10−8), passed the SMR 
analysis (P = 2.95 × 10−8) and HEIDI test (P = 0.258). We performed the same test on 
macrophage expression data obtained from Cardiogenics and rs316341 passed the SMR 
analysis (P = 1.23 × 10−7) and HEIDI test (P = 0.240). This suggests that the locus 
associated with CSF Aβ42 is the same locus that affects expression of SERPINB1 in blood 
and macrophages.
The other genetic loci for Aβ42 and ptau181 were not as enriched for significant eQTL 
effects as SERPINB1, but there were suggestive results for 1p32.3 (near GLIS1) and 18q23 
(near CTDP1). The signal near GLIS1 associated with Aβ42 (1p32.3) had an eQTL effect on 
SLC1A7 throughout the brain (rs185031519[G]: P = 8.8 × 10−5); however, overall 
expression of SLC1A7 was reported to be relatively low in the human brain, within the 33rd 
percentile of all gene expression in the temporal cortex, primarily in endothelial cells [84] 
(Supplementary Table 13). The locus on 18q23 associated with ptau181, between CTDP1 
and NFATC1, may have eQTL effects on both genes in the frontal cortex (rs12961169[T]: 
CTDP1, β = −0.319, P = 3.85 × 10−5 ; NFATC1, β = −0.290, P = 1.71 × 10−5). Both 
NFATC1 and CTDP1 are expressed in the human temporal cortex (NFATC1 = 58th 
percentile; CTDP1 = 37th percentile; Supplementary Table 13).
Effect of AD risk loci on CSF levels
We wanted to determine whether known loci for AD risk are also associated with CSF levels 
of Aβ42 or ptau181. AD risk variants identified in the IGAP study [48] that were most 
significantly associated with Aβ42 were located in the CLU (β = 0.014, P = 0.001) and 
FERMT2 (β = −0.018, P = 0.009) gene regions, and SNPs in the CELF1 and ABCA7 
regions had P < 0.05 (Supplementary Table 11). For CSF ptau181 levels, the most significant 
association was in the INPP5D region (β = 0.014, P = 0.009) and the CR1, PICALM, and 
FERMT2 regions had P < 0.05 (Supplementary Table 11). These results suggest that the risk 
variant in the CLU locus (rs11136000[T]) may increase risk for AD through an Aβ-
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associated mechanism and the INPP5D locus by a ptau-associated mechanism. Other loci 
like APOE or FERMT2 may act through both Aβ- and ptau-associated pathways to affect 
AD risk, and still other risk loci may act through alternate mechanisms such as neuronal 
survival, apoptosis, or homeostasis.
Although the individual AD risk variants were not strongly associated with Aβ42 or ptau181, 
we decided to analyze the potential overlap in the genetic architecture of AD risk and these 
endophenotype levels by determining whether PRS (with or without the effect of APOE 
genotype) calculated from the genome-wide significant hits for AD risk are also associated 
with CSF levels. We found not only a strong association between the non-APOE PRS and 
Aβ42 (β = −0.033, P = 5.01 × 10−7), but also tau (β = 0.049, P = 1.38 × 10−7) and ptau181 (β 
= 0.049, P = 1.81 × 10−8) (Supplementary Table 11). The strength of the association with the 
non-APOE PRS was greater than any of the individual SNPs composing the PRS. The 
addition of APOE genotype significantly increased the PRS association with CSF levels 
(Aβ42: β = −0.065, P = 5.01 × 10−88; tau: β = 0.051, P = 1.38 × 10−31; and ptau181: β = 
0.044, P = 1.81 × 10−31) (Supplementary Table 11).
Estimation of CSF level variance explained by associated genetic loci
To determine the proportion of phenotypic variance (h2) explained by the genetic loci 
identified for Aβ42 and ptau181, we analyzed all of the tested genotyped and imputed 
autosomal common variants (MAF > 0.02). It was recently demonstrated that estimated h2 
may be biased if causal variants are enriched in areas with lower or higher LD than average 
[81], so we used the GCTA tool to calculate segment-based LD scores (segment length = 
200 kb) for all SNPs and plotted the number of SNPs with P < 1 × 10−5 for Aβ42 and 
ptau181 (Supplementary Fig. 12). Since we observed LD heterogeneity in the associated 
variants, and the LDMS method can be applied to imputed GWAS data, we used the GCTA 
LDMS method to test all SNPs in our genetic data [81]. After correcting for age, sex, and 
two principal components, approximately 35.5% of the variability in Aβ42 and 24.9% in 
ptau181 levels were explained by common variants; the respective SNPs associated with CSF 
Aβ42 and ptau181 with P < 1 × 10−5 only accounted for 3.5% (2.9% from chromosome 19) 
of the variability in Aβ42 levels and 3.2% (1.4% from chromosome 19) in ptau181 levels, 
corresponding to 10 and 13% of the estimated h2 for CSF Aβ42 and ptau181, respectively. 
These results suggest many genetic variants have yet to be discovered.
Discussion
Genetic studies using disease endophenotypes as quantitative traits provide power to identify 
loci associated with disease risk with smaller sample sizes, and endophenotypes provide 
biological context to help identify loci associated with other disease phenotypes such as 
AAO and disease progression. In our previous study using CSF levels of Aβ42 and ptau181 
as endophenotypes, rs9877502 (near GMNC1 on 3q28) was reported, for the first time, to be 
associated with ptau181 levels, AD risk, tangle pathology, and cognitive decline [13]. The 
ptau181 association was recently replicated in an independent cohort [63] and we confirmed 
the association in this much larger dataset. The GMNC1 locus was also recently reported to 
be associated with intracranial volume [1], suggesting that tau-associated pathology and 
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brain volume share some genetic architecture. This larger study also revealed novel loci 
associated not only with Aβ42 but also with AD risk and disease progression 
(rs185031519[G], (rs185031519[G], P = 3.43 × 10−2 and P = 1.92 × 10−2, respectively), or 
AAO (rs316341[G], P = 4.62 × 10−3). The associations with AD risk and AAO were tested 
in independent datasets. The associations of these SNPs with risk, disease progression, and 
AAO may not pass stringent multiple test correction if we take into account the number of 
SNPs and phenotypes tested. However, it is important to note that we had a very specific 
hypothesis, including direction of effect, for each SNP. As expected, the alleles associated 
with lower CSF levels of Aβ42 were also associated with earlier disease symptom onset, 
increased AD risk, or faster progression. In any case, the associations with risk, disease 
progression, and AAO were identified in the largest datasets available to date, but additional 
studies will be needed to confirm the role of these loci in AD. By increasing the sample size 
more than twofold, we not only verified the results from our previous analyses, but also 
uncovered additional findings that can be used to inform future AD studies.
APOE genotype is the strongest genetic risk factor for sporadic AD, and is consistently the 
strongest association with CSF levels of Aβ42, tau, and ptau181 in several GWAS as well [13, 
36, 46, 63]. Numerous studies have explored how APOE influences amyloid pathology in 
AD [67]. A few studies have also looked at the role of ApoE in tau pathology [30, 49, 52]. A 
recent study of brain tissue from 1056 individuals (659 AD cases) found that the APOE ε4 
and ε2 alleles were not associated with tau tangle pathology in the absence of amyloid 
deposits [27]. As we previously reported, after accounting for CSF Aβ42, there was a strong 
association for APOE with CSF ptau181, although it no longer passed genome-wide 
significance [13]. We verified these results in the current study, and with the larger dataset 
the APOE signal remained genome-wide significant after accounting for Aβ42 levels. This 
provides additional evidence that APOE influences ptau181-associated mechanisms of AD 
independently of Aβ42-associated mechanisms. We also found, through conditional 
analyses, that although APOE genotype is driving most of the association for APOE with 
CSF Aβ42 and ptau181, there appears to be an additional signal within the APOE gene region 
that is independent of APOE ε2, ε3, and ε4.
CSF Aβ42 and ptau181 are well-established AD endophenotypes with a clear common 
genetic association for APOE and AD risk, but the shared genetic architecture between the 
disease and AD biomarkers is not as well-understood [7, 13–15]. Shared heritability 
between two traits can be estimated using different methods to calculate genetic and 
phenotypic correlations by linear mixed models, LD scoring, or genome partitioning; but 
most methods currently available usually require sample sizes in the tens of thousands to 
counteract statistical noise [3, 9, 10, 12, 66]. Another method to detect shared genetic 
etiology between traits is to calculate a PRS from a well-characterized cohort, usually from 
large case–control GWAS, and regress the other trait of interest, such as CSF protein levels, 
on the PRS in an independent cohort [21, 24]. Small studies (N < 350) have found that PRS 
were negatively correlated with CSF Aβ42 but not correlated with tau or ptau181 [54, 65, 71]. 
Recent studies of AD cases (N = 338) or individuals with mild cognitive impairment (N = 
454), reported that their PRS without APOE were not associated with Aβ42, but tau and ptau 
were associated with the score without the APOE effect [53, 71]. In our current study of 
both AD cases and controls (N = 3145), we calculated a PRS composed of genome-wide 
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significant AD risk loci that were reported in the largest AD case–control GWAS thus far 
[48]. Since the APOE locus is strongly associated with CSF levels and AD risk, it is not 
unexpected that PRS that include APOE effect would also be significantly associated with 
Aβ42 and ptau181. Calculating PRS without including the APOE effect can provide 
information about the much smaller genetic effect of other AD risk loci, and although the 
individual variants were not even suggestively significant the PRS was significantly 
associated with both proteins. This suggests there is a genetic overlap between AD risk and 
the CSF biomarkers that is not apparent in single variant analyses. Since we restricted the 
PRS to genome-wide significant AD risk loci, we may actually be underestimating genetic 
overlap between AD risk and CSF Aβ42 and ptau181. Some of the AD risk loci did not 
appear to be associated with either biomarker, suggesting they affect AD risk through 
mechanisms independent of Aβ42 and ptau181. Some AD risk loci such as CLU and 
PERMT2 for Aβ42 and INPP5D for ptau181 may be associated with these AD 
endophenotypes but did not reach genome-wide significance. Reasons for this could be that 
multiple risk loci interact to influence CSF levels, or possibly a lack of power due to small 
effect size of the individual variants. For example, we estimated that at least 4500 samples 
would be necessary for the association for CLU with Aβ42 to pass the genome-wide 
significance threshold (P < 5 × 10−8), suggesting that additional signals could be identified 
with a larger sample size.
Genetic studies of endophenotypes not only provide enough power to identify novel 
associations with smaller sample sizes than case–control studies, but can also help with 
understanding biological mechanisms of disease. Loci identified in this study alter gene 
expression or protein binding, which can provide valuable information for understanding the 
biological basis for AD pathology. We identified here, for the first time, two genome-wide 
significant signals for CSF Aβ42 outside the APOE region. Of particular interest is the locus 
on 6p25 which is associated with lower CSF Aβ42 and earlier AAO. This may be mediated 
through SERPINB1, because the same SNPs affect SERPINB1 expression in blood and 
macrophages. SERPINB1 encodes a serine protease inhibitor that is a key regulator of 
neutrophil programmed cell death [28, 50]. SERPINB1 is expressed in the human brain, 
primarily in microglia and macrophages [84]. Recent research of transgenic mouse models 
for AD (5×FAD and 3×Tg-AD) reported that neutrophils were present in the brain near Aβ 
deposits, and researchers observed neutrophil migration from blood into the brain toward 
amyloid plaques [4, 83]. They discovered that Aβ42 triggered the high-affinity state of 
integrin LFA-1, which is necessary for neutrophil infiltration of the CNS [83]. Their results, 
combined with our findings that genetic variants that increase expression of SERPINB1 are 
also associated with lower levels of Aβ42, support other studies suggesting that immune 
response pathways may play a key role in AD pathology [38, 75]. Our results indicate a 
potential role for SER-PINB1 in AD and suggest that adaptive immune response 
mechanisms are associated with Aβ-mediated pathology. Key proteins in 
neuroinflammation, triggering receptor expressed on myeloid cells 2 (TREM2) and 
YKL-40, are promising AD biomarkers [59, 60], and TREM2 variants are also strongly 
associated with AD risk [6, 34, 42]. Clusterin (CLU) has been associated with AD risk in 
numerous studies [37, 48] and a GWAS of CSF CLU levels suggested CLU may be 
associated with immune response [20]. Our findings add to this growing evidence that 
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immune response plays a key role in AD and CSF levels of Aβ42 may be representative of 
this role.
The associations of the GMNC locus with ptau181 levels and brain volume suggest 
biological mechanisms other than immune response may be associated with tau-mediated 
pathology in AD [1, 13, 63]. Although not well studied, GMNC (also known as GEMC1) is 
a necessary regulator of DNA replication [5] and recently was shown to be a key player in 
the differentiation of radial glial cells to multiciliated neuroepithelial cells during 
neurogenesis in the sub-ventricular zone [47]. Combined with our GWAS results, it appears 
GMNC may influence CSF ptau181 as part of the neurogenesis process. Further research is 
needed to determine if GMNC is indeed the gene affecting ptau181 and what biological 
mechanism is involved. However, some of the loci associated with ptau181 suggest immune 
response may also play a role in tau-associated pathology. NFATC1 encodes the nuclear 
factor of activated T-cells cytoplasmic 1 protein which is important in gene transcription 
induced by immune response. CTDP1 encodes the RNA polymerase II subunit A C-terminal 
domain phosphatase which interacts with the TFIIF transcription factor. Both NFATC1 and 
CTDP1 are expressed in the human temporal cortex, NFATC1 (58th percentile) more so than 
CTDP1 (37th percentile). NFATC1 is also the more promising candidate than CTDP1 
because CTDP1 is primarily expressed in fetal astrocytes and nominally in other cell types, 
while NFATC1 is predominantly expressed in microglia and macrophages [84] 
(Supplementary Table 13). We were unable to test for the putative causal variant in these 
regions for these eQTL effects. However, these data suggest the top loci may influence 
ptau181 levels by affecting expression of these genes.
In summary, by increasing the sample size more than twofold we not only verified the 
results from our previous analyses, but also uncovered additional findings that can be used to 
inform future AD studies. We identified novel associations between genetic loci and CSF 
levels that may provide insight into the biological mechanisms that affect protein levels, 
influence AD risk, AAO, and disease progression. Our findings suggest CSF Aβ42 levels 
may be representative of the role of immune response on Aβ-associated pathology, and that 
this role may influence AAO. Although immune-related genes may be associated with 
ptau181, our results suggest that CSF ptau181 may reflect pathways related to neurogenesis 
and brain volume. Although we did not identify individual AD risk variants outside the 
APOE region, the PRS results indicate shared genetic architecture between AD risk and 
these CSF biomarkers. Larger studies using AD endophenotypes will likely provide even 
more information to help understand the biology underlying AD pathology.
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Fig. 1. 
Association plots from single variant analyses of CSF ptau181 levels. a Manhattan plot 
shows negative log10-transformed P values from the joint analysis of ptau181. The horizontal 
lines represent the genome-wide significance threshold, P = 5 × 10−8(red) and suggestive 
threshold, P = 1 × 10−5(blue). Red arrows point to novel loci. The y-axis is truncated, the 
lowest P value on chromosome 19 was 5.30 × 10−33.b, c Regional association plots of novel 
loci are shown for SNPs associated with ptau181 near PCDH8 (a) and between NFATC1 and 
CTDP1 (b). The SNPs labeled on each regional plot had the lowest P value at each locus and 
are represented by a purple diamond. Each dot represents a SNP and dot colors indicate LD 
with the labeled SNP. Blue vertical lines show recombination rate marked on the right-hand 
y-axis of each regional plot. Plots for previously reported loci are in Supplementary Fig. 7
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Fig. 2. 
Association plots from single variant analyses of CSF Aβ42. a Manhattan plot shows 
negative log10-transformed P values from the joint analysis of Aβ42. The horizontal lines 
represent the genome-wide significance threshold, P = 5 × 10−8(red) and suggestive 
threshold, P = 1 × 10−5(blue). Red arrows point to novel loci. The y-axis is truncated, the 
lowest P value on chromosome 19 was 4.78 × 10−94. b, c Regional association plots of novel 
loci are shown for SNPs associated with Aβ42 near GLIS1 (b) and within SERPINB1 (c). 
The SNPs labeled on each regional plot had the lowest P value at each locus and are 
represented by a purple diamond. Each dot represents a SNP and dot colors indicate LD with 
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the labeled SNP. Blue vertical lines show recombination rate marked on the right-hand y-
axis of each regional plot. Plots for previously reported loci are in Supplementary Fig. 7
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